COVID-19

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to...

Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology

MALVERN, Pa., March 10, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing...

Microbot Medical’s Chief Medical Officer Dr. Eyal Morag to Highlight Performance, Safety and Usability Benefits of the LIBERTY® Robotic System During Podium Presentation at Prestigious Robotics Conference

error: Content is protected !!